Orakine Limited
Orakine Limited was formed to commercially exploit the proprietary technology developed to take advantage of natural cytokine therapy through simple contact with the oromucosal tissue and subsequent cellular activation and trafficking. This patented and novel technology will revolutionise the €12 billion cytokine pharmaceutical market.

Cytokines, such as IFN, are proteins that are produced in human tissues, in minute amounts, and play an important role in maintaining the normal functions of human metabolism and fighting disease. Since they are secreted proteins they have been among the first products of the biopharmaceutical industry. The processes of biotechnology allow the manufacture of these proteins in unlimited amounts at reasonable costs. Because current therapies require injection of cytokine directly into the patient's blood, these powerful drugs often have severe side-effects. Orakine's sublingual cytokine therapy represents the most natural route of administration and completely avoids the toxicity of these proteins.